adverse drug events (ADE)

A new analysis of dozens of animal studies evaluating the effects of the cholesterol-lowering statin class of drugs on atherosclerosis found larger positive effects in studies not sponsored by the pharmaceutical industry as compared to those that were industry sponsored.

In the current issue of The Archives of Internal Medicine, two faculty members of the UCSF School of Pharmacy, Department of Clinical Pharmacy issue a call for prioritization in prescription labels’ increasingly long lists of adverse drug events (ADEs).